Physician profile
Brian K Sugimoto
NPI 1700814902
$47,291.65
in general payments reported to CMS, 2019-2025
14 companies · $4,613 in 2025
The $4,613 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,901 · 2020: $1,444 · 2021: $7,945 · 2022: $4,265 · 2023: $6,640 · 2024: $12K · 2025: $4,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $23K · Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $22,813.00 |
| Food and Beverage | $922.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $33,581.90 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $12,564.67 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $480.50 | 2023 | Vital, Virage |
| Zimvie INC. | $327.52 | 2022-2023 | |
| Hologic Sales and Service, LLC | $80.09 | 2019-2024 | Thinprep 2000 Processor |
| Pfizer INC. | $58.89 | 2019 | |
| Smith+Nephew, INC. | $51.43 | 2024 | Collagenase Santyl, Regranex |
| Bayer Healthcare Pharmaceuticals INC. | $32.94 | 2024-2025 | |
| Novo Nordisk INC | $31.86 | 2025 | Ozempic, Rybelsus |
| Orthofix Medical, INC. | $21.84 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.25 | 2022 | |
| Glaxosmithkline, LLC. | $16.20 | 2020 | |
| Amarin Pharma, INC. | $14.80 | 2020 | |
| Sanofi Pasteur INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sugimoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.